Mariam Elmegaard

@KristofferSkaar @lundbeckfonden @TorBiering @CIRL Stort tillykke K, hvor er det flot! 👏🏼😃

I'm honored to be selected as one of the five prize recipients for the @lundbeckfonden Talent Prize. A big congratulations also goes to my mentor @TorBiering for receiving this year's Young Investigator award! @cirl

New: Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study by @MariamElmegaard and colleagues thelancet.com/journals/lanhl…

Selvom ældre og skrøbelige patienter kan have særlig god gavn af behandling med SGLT2-hæmmere og GLP-1-receptoragonister for type-2 diabetes, hjertekarsygdom og nyresygdom, bliver de alt for sjældent startet op i behandlingerne #sundpol buff.ly/3PSa1j4

In this cross-sectional nationwide @LancetLongevity study @MariamElmegaard and @mortschou et al showed #frailty was associated with a ⬇️lower probability of SGLT2-inhibitor or GLP-1 receptor-agonist initiation, despite their benefits Free 🔗 thelancet.com/journals/lanhl…

@gunngis Skarpt billede 🔥

Så er jeg klar til #Hjertegalla i aften 💓 Glæder mig til at fejre hjerterne og nyde et fantastisk show 🤩

👏@MariamElmegaard presented her impressive study in light of the new ESC 2023 guidelines for the management of CVD in T2D. Should we focus more on preventing cardiorenal disease in patients without established CVD and CKD 🤔? #ESCCongress @cardio_dk #DCS_ESC23 @mortschou

It can be difficult to discern high quality observational studies from the rest. But it is critical that we try. Sharing some of the things I've learned here: Bringing the Credibility Revolution to Observational Research in Cardiology | Circulation ahajournals.org/doi/10.1161/CI…

Just out in European Heart Journal @ESC_Journals: 2001-2019 - CHD💔patients faced ⬆️ rates of #OHCA🧎🏻cmprd w cntrls across severities🧮. But equal 30d survival due to pre-hospital chain academic.oup.com/eurheartj/adva… #ACHD #CVD #cardiotwitter #escardio @CopCard @ehj_ed @BarcellaCarlo

@CopCard @MortenLamberts @Hjerteforening Stort tillykke! Hvor er det fantastisk 🥳

@MortenLamberts and his team out celebrating the funding from @Hjerteforening for the project VIR-SAAF 🫀A huge congrats! 🎊 hjerteforeningen.dk/2023/06/hjerte…

@CardiologyZuh @AFalkentoft @ARuwald @NielsEskeBruun Stort tillykke! 💐

🎉Congratulations to @AFalkentoft on successfully defending his PhD thesis “Impact of Socioeconomics and Pharmacological Treatment Delay on Cardiovascular Mortality in Patients with Type 2 Diabetes”!🎉

@lucas_yxing @DagensMedicinDK @cardio_dk @SZDiederichsen @RigsHeart @dkforsk Amazing work 👏🏼

Thrilled to have presented our research on NT-proBNP🩸 and the effects of #Afib screening🫀at the Annual Meeting for Danish Society of Cardiology #dcs2023 🗣️Our findings have also been featured in @DagensMedicinDK! Read the article here: dagensmedicin.dk/biomarkoer-ken…

@cardio_dk @m_chouli @DeewaZahir @OscarWestin @HFA_President Så sejt gået! 👏🏼

I ifm #HeartFailureAwarenessDays var @m_chouli , @DeewaZahir og Morten Malmborg til fredagsbøn i Stormoskéen på Nørrebro 🕌 på vegne DCS’ HF gruppe @OscarWestin bidrog med posters Her blev tilbudt, BT-måling og V-scan af hjertet🔉 Det var en kæmpe succes‼️ @HFA_President

@CopCard @ClinEpidem @SebKinnberg @MortenLamberts @mortschou @NinaNouhravesh @MadsHashiba Well done @SebKinnberg 👏🏼🥇

In this @ClinEpidem paper @SebKinnberg et al found that a procedure based definition of cancer status (I.e, active and non-active) is valid in breast-, lung- and colorectal cancer ✅ dovepress.com/getfile.php?fi…

In this @JACCJournals sdy of >330,000 pts w DM @AndersHolt6 et al found asso between short-term NSAID use and ⬆️ w solid fill risk of HF, strongest asso in age >79 and elevated HbA1c. 😊 bit.ly/43pNbE4 #CardioTwitter

Nationwide, case-crossover study of >330k pts w/ #diabetes found assoc between short-term #NSAID use and risk of #HF, strongest assoc in age >79 & elevated HbA1c. Results could help physicians mitigate risk if prescribing NSAIDs for diabetes pts. bit.ly/3KutBhj #JACC

@m_chouli @DanielMolager @Hjerteforening @CopCard @gunngis @JarlStrange Du gjorde det fantastisk @DanielMolager 👏🏼 stort tillykke endnu engang

Temporal trends in incidence and prognosis of #myocardialinfarction and risk prediction in #CVD in this PhD-defence by the naturally talented @DanielMolager from @Hjerteforening. What a pleasure to behold! @CopCard #rstats #riskprediction #colliderbias

In this @TheLancet sdy @MariamElmegaard et al found that in 77,745 ptts w first time SGLT2-is and 56,037 GLP1-RAs the risk of discontinuing was 56% and 45%, respectively, w a decreased risk over the sdy-period thelancet.com/journals/lanep… #Cardiotwitter @cardiology @diabetes

Data on all Danish first-time users of SGLT2is and GLP1-RAs from 2013 to 2021 show that ~50% discontinued therapy within five years, but a quarter of these reinitiated therapy during the following year. Discontinuation rates decreasing with time. thelancet.com/journals/lanep…

A poem by prof. Thomas Gerds (and #ChatGPT) on why you should always include a statistician in planning an RCT 🎯 @CopCard #CardioTwitter @diskotex🥇

Heading home to 🇩🇰 from this years #ACC #WCC. What an experience!